DEPAKOTE Drug Patent Profile

✉ Email this page to a colleague

When do Depakote patents expire, and what generic alternatives are available?

Depakote is a drug marketed by Abbvie and Abbott and is included in four NDAs.

The generic ingredient in DEPAKOTE is divalproex sodium. There are eighteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Depakote

A generic version of DEPAKOTE was approved as divalproex sodium by APOTEX on July 29^th, 2008.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DEPAKOTE?
What are the global sales for DEPAKOTE?
What is Average Wholesale Price for DEPAKOTE?

Summary for DEPAKOTE

US Patents:	0
Applicants:	2
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	97
Patent Applications:	4,850
Drug Prices:	Drug price information for DEPAKOTE
Drug Sales Revenues:	Drug sales revenues for DEPAKOTE
What excipients (inactive ingredients) are in DEPAKOTE?	DEPAKOTE excipients list
DailyMed Link:	DEPAKOTE at DailyMed

Drug patent expirations by year for DEPAKOTE

Recent Clinical Trials for DEPAKOTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Puma Biotechnology, Inc.	Phase 1/Phase 2
Virginia Commonwealth University	Phase 1/Phase 2
Barretos Cancer Hospital	Early Phase 1

See all DEPAKOTE clinical trials

Pharmacology for DEPAKOTE

Drug Class	Anti-epileptic Agent Mood Stabilizer
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for DEPAKOTE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	DEPAKOTE	divalproex sodium	CAPSULE, DELAYED REL PELLETS;ORAL	019680-001	Sep 12, 1989	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	DEPAKOTE ER	divalproex sodium	TABLET, EXTENDED RELEASE;ORAL	021168-002	May 31, 2002	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	DEPAKOTE	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	018723-002	Mar 10, 1983	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DEPAKOTE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	DEPAKOTE	divalproex sodium	CAPSULE, DELAYED REL PELLETS;ORAL	019680-001	Sep 12, 1989	⤷ Sign Up	⤷ Sign Up
Abbvie	DEPAKOTE	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	018723-003	Oct 26, 1984	⤷ Sign Up	⤷ Sign Up
Abbvie	DEPAKOTE	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	018723-001	Mar 10, 1983	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DEPAKOTE

See the table below for patents covering DEPAKOTE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Italy	8024207		⤷ Sign Up
Italy	1148718	SALE MISTO DI ACIDO VALPROICO	⤷ Sign Up
European Patent Office	0034172	MIXED SALT OF VALPROIC ACID	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DEPAKOTE

Recent Clinical Trials for DEPAKOTE

Pharmacology for DEPAKOTE

Make Better Decisions: Try a trial or see plans & pricing